Page 17 - Package Leaflet News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Johnson & Johnson COVID-19 Vaccine Rollout to Resume in Europe On Apr 21, 2021 New Brunswick-based Johnson & Johnson announced that the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the company’s COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks foll...

TOP NEWS: J&J to restart rollout of Covid-19 jab on EMA guidance Tue, 20th Apr 2021 17:36 (Alliance News) - Johnson & Johnson on Tuesday announced that it will resume the rollout of its Covid-19 vaccine in Europe following the European Medicines Agency's updated guidance for the jab. The EU's drug watchdog announced earlier Tuesday that blood clots should be listed as a "very rare" side effect of the J&J coronavirus vaccine but its benefits still outweigh the risks. The guidance follows a review of a small number of cases of a rare adverse event involving blood clots in combination with low p...

Share this article Share this article NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company's COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following i...

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY® News Provided By Share This Article ®, bringing total doses to 600 million for 27 EU member states All doses expected to be delivered in 2021  BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY ®, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a result of the European Commission’s (EC) decision to exercise its option to purchase an additional 100 million doses under its expand...

Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY® New agreement brings total supply to the European Union to 500 million doses, with delivery expected by the end of 2021 European Commission has the option to request an additional 100 million doses NEW YORK and MAINZ, GERMANY, February 17, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY ®, the companies’ COVID-19 vaccine, to the 27 European Unio...